A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes.
Quynh N Mai, Priyank Shenoy, Tim Quach, Jeffri S Retamal, Arisbel B Gondin, Holly R Yeatman, Luigi Aurelio, Joshua W Conner, Daniel P Poole, Meritxell Canals, Cameron J Nowell, Bim Graham, Thomas P Davis, Stephen J Briddon, Stephen J Hill, Christopher JH Porter, Nigel W Bunnett, Michelle L Halls, Nicholas A Veldhuis
Journal of Biological Chemistry | Published : 2021
G protein-coupled receptors (GPCRs) are traditionally known for signaling at the plasma membrane, but they can also signal from endosomes after internalization to control important pathophysiological processes. In spinal neurons, sustained endosomal signaling of the neurokinin 1 receptor (NK1R) mediates nociception, as demonstrated in models of acute and neuropathic pain. An NK1R antagonist, Spantide I (Span), conjugated to cholestanol (Span-Chol), accumulates in endosomes, inhibits endosomal NK1R signaling, and causes prolonged anti-nociception. However, the extent to which the Chol-anchor influences long-term location and activity is poorly understood. Herein, we used fluorescent correlati..View full abstract